Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

COVID-19 Clinical Trial

Official title:

A Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in the Treatment of Patients With Moderate COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05770466
• Other study ID #: 202108013MIPC
• Status: Completed
• Phase: Phase 3
• Start date: April 1, 2022
• Est. completion date: January 11, 2023

Study information

• Verified date: April 2022
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101combined with standard of care (SOC) compared with standard care alone in hospitalized adults with moderate COVID 19.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: January 11, 2023
• Est. primary completion date: December 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Ability to comprehend and willingness to provide a written ICF before enter the study;

2. Male or non-pregnant female patients, = 20 years of age at the time of enrolment;

3. Hospitalized patient with a diagnosis of COVID-19 on the basis of a positive# reverse transcriptase polymerase chain reaction (RT-PCR) with moderate## disease on admission###. #: Ct value <30. ##:Disease severity as defined by the treatment guidance of Taiwan Centers for Disease Control (CDC):

> Moderate: Pneumonia patients without severe symptoms, blood oxygen saturation =93% without supplemental oxygen equipment (on room air); ###: Confirmed positive RT-PCR result = 4 days prior to screening visit is eligible

4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.

Exclusion Criteria:

1. Known history or presence of decompensated cirrhosis of the liver (Child-Pugh B or C) before study entry.

2. Patients with intubation, respiratory failure, septic shock, multiple organ dysfunction or need additional organ support (e.g. vasopressors or ECMO).

3. Patients who have SpO2 <93% on room air, respiratory frequency >30 breaths/min.

4. Patients treated by dexamethasone before Day 1.

5. Patients treated by supplemental oxygen (FiO2 >40%) before Day 1.

6. Stage =4 severe chronic kidney disease or requiring dialysis (i.e. eGFR <15 mL/min/1.73 m2).

7. Females who are breast-feeding, lactating, pregnant or intending to become pregnant.

8. Known history of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa-2b.

9. Known history or presence of poorly controlled or clinically significant medical conditions that are not suitable to be enrolled, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt).

11. Clinically significant medical conditions known to interfere with absorption, distribution, metabolism or excretion of the study drugs.

12. Patients treated by monotherapy of telbivudine or any other combination therapy with telbivudine within 1 month prior to screening.

13.Therapy with any anti-neoplastic, or immunomodulatory treatment within 1 month prior to screening.

14. Patient who have been vaccinated with any live attenuated vaccine or COVID- 19 vaccine within 1 month prior to screening.

15. Use of an investigational medical product within 1 month prior to screening.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• P1101 (Ropeginterferon alfa-2b)
Name: P1101 (Ropeginterferon alfa-2b) Dosage form: pre-filled syringe Strength: A single dose of 250 mcg/0.5 mL Dosage and administration: 250 mcg per subcutaneous injection Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines

Procedure:
• SOC
SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients who are negative to SARS-CoV-2 at Day 8	Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value =30) RT-PCR at Day 8 or discharge before Day 8 due to recovery	Up to Day 8
Primary	Time to discharge from hospital	Time to discharge from hospital according to the latest Taiwan CDC guidance for SARS-CoV-2 infection (From randomization to discharge)	Up to Day 29
Secondary	Proportion of patients who are negative to SARS-CoV-2 at Day 5	Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value =30) RT-PCR at Day 5 or discharge before Day 5 due to recovery	Up to Day 5
Secondary	Change in clinical status of patient at Day 5	Change in clinical status of patient on WHO clinical progression scale at Day 5	Up to Day 5
Secondary	Change in clinical status of patient at Day 8	Change in clinical status of patient on WHO clinical progression scale at Day 8	Up to Day 8
Secondary	Change of SpO2	Change of SpO2 from baseline	Up to Day 29
Secondary	Time from symptom onset to resolution of clinical signs and symptoms	Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the resolution of clinical signs and symptoms.	Up to Day 29
Secondary	Time from symptom onset to RT-PCR negative result	Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the RT-PCR negative result (Ct value =30).	Up to Day 29
Secondary	Time from RT-PCR positive result to the resolution of clinical signs and symptoms	Time from RT-PCR positive result (Ct value < 30) to the resolution of clinical signs and symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell)	Up to Day 29
Secondary	Time from RT-PCR positive result to RT-PCR negative result	Time from RT-PCR positive result (Ct value < 30) to RT-PCR negative result (Ct value =30)	Up to Day 29
Secondary	Occurrence and duration (days) of supplemental oxygen	Occurrence and duration (days) of supplemental oxygen	Up to Day 29
Secondary	Occurrence and duration (days) of mechanical ventilation	Occurrence and duration (days) of mechanical ventilation	Up to Day 29
Secondary	Time to treatment with other antiviral agents within 8 days	To evaluate the time to treatment with other antiviral agents within 8 days in the Ropeginterferon alfa-2b treatment group,	Up to Day 8